Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha 2b: relation to response and HBV genotype

Tarih
2012
Yazar
Mach, Tomasz
Boucher, Charles A. B.
Hansen, Bettina E.
Zeuzem, Stefan
Janssen, Harry L. A.
Cakaloglu, Yilmaz
Tabak, Fehmi
Sonneveld, Milan J.
Rijckborst, Vincent
Simon, Krzysztof
Heathcote, E. Jenny
Üst veri
Tüm öğe kaydını göster
Özet
Background: On-treatment decline of serum hepatitis B surface antigen (HBsAg) may reflect the immunomodulatory effect of pegylated interferon (PEG-IFN) for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). We compared HBsAg decline across HBV genotypes between combined responders (HBeAg loss and HBV DNA 10,000 copies/ml) and non-responders.
Bağlantı
http://hdl.handle.net/20.500.12627/22267
https://doi.org/10.3851/imp1887
Koleksiyonlar